

Ana I Casanegra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/533273/publications.pdf>

Version: 2024-02-01

27
papers

440
citations

933447

10
h-index

752698

20
g-index

27
all docs

27
docs citations

27
times ranked

735
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2467-2486.	3.0	91
2	Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. <i>American Journal of Hematology</i> , 2019, 94, 1185-1192.	4.1	44
3	Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. <i>Thrombosis Research</i> , 2017, 154, 28-34.	1.7	36
4	Association of ACE genotype and predominantly diastolic hypertension: a preliminary study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 42-44.	1.7	31
5	Monitored Daily Ambulatory Activity, Inflammation, and Oxidative Stress in Patients With Claudication. <i>Angiology</i> , 2014, 65, 491-496.	1.8	27
6	Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1242-1252.	3.0	26
7	Risk of venous thromboembolism after COVID-19 vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1638-1644.	3.8	24
8	Prevention of Femoropopliteal In-Stent Restenosis With Cilostazol. <i>Angiology</i> , 2016, 67, 549-555.	1.8	21
9	Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2793-2805.	3.0	20
10	Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight. <i>European Journal of Haematology</i> , 2020, 105, 484-494.	2.2	19
11	Cognitive decrement in older adults with symptomatic peripheral artery disease. <i>GeroScience</i> , 2021, 43, 2455-2465.	4.6	13
12	Differences in galectin-3, a biomarker of fibrosis, between participants with peripheral artery disease and participants with normal ankle-brachial index. <i>Vascular Medicine</i> , 2016, 21, 437-444.	1.5	11
13	Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2206-2215.	3.8	11
14	Adverse Events and Mortality in Anticoagulated Patients with Different Categories of Pulmonary Embolism. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 249-258.	2.4	10
15	In-home Compared With In-Clinic Warfarin Therapy Monitoring in Mechanical Heart Valves: A Population-Based Study. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 511-520.	2.4	9
16	Artificial intelligence for the evaluation of peripheral artery disease using arterial Doppler waveforms to predict abnormal ankle-brachial index. <i>Vascular Medicine</i> , 2022, 27, 333-342.	1.5	8
17	Calf Vein Thrombosis Outcomes Comparing Anticoagulation and Serial Ultrasound Imaging Management Strategies. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1184-1192.	3.0	7
18	Elders' Environments and Their End-Of-Life Preferences. <i>Journal of the American Medical Directors Association</i> , 2011, 12, 22-28.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Diet is associated with ankle-brachial index, inflammation, and ambulation in patients with intermittent claudication. <i>Journal of Vascular Surgery</i> , 2020, 72, 1375-1384.	1.1	5
20	Raynaud Phenomenon and Other Vasospastic Disorders. <i>Cardiology Clinics</i> , 2021, 39, 583-599.	2.2	5
21	Single versus multiple and incidental versus symptomatic subsegmental pulmonary embolism: clinical characteristics and outcome. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 82-90.	2.1	5
22	Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12500.	2.3	4
23	Pulmonary artery capacitance and pulmonary vascular resistance as prognostic indicators in acute pulmonary embolism. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	3
24	Usability of a Digital Registry to Promote Secondary Prevention for Peripheral Artery Disease Patients. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 94-102.	2.4	2
25	Major adverse events associated with inducible cardiac ischemia during treadmill exercise testing for peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2021, 74, 1335-1342.e2.	1.1	2
26	Improved trainee experience with a structured subspecialty rotation. <i>Medical Education</i> , 2015, 49, 1148-1149.	2.1	0
27	Demographics and Clinical Outcomes in Patients Older Than 75 Years Treated for Acute Venous Thromboembolism. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, e151-e153.	0.9	0